BRAF and neoplasm: The potential for long-term survival with second-line BRAF/MEKi should be considered by patients and physicians when choosing other potential treatment options in this setting including clinical trials or, if approved in the future, adoptive cell therapy with tumor-infiltrating lymphocytes (TIL).24 Nevertheless, the 2-year PFS rate was only 17.5%, clearly indicating the need to develop more effective therapies.